DK169271B1 - 8-Phenylxanthinderivater, fremgansmåde til fremstilling heraf, farmaceutisk præparat indeholdende en sådan forbindelse, samt en sådan forbindelse til anvendelse til terapi - Google Patents

8-Phenylxanthinderivater, fremgansmåde til fremstilling heraf, farmaceutisk præparat indeholdende en sådan forbindelse, samt en sådan forbindelse til anvendelse til terapi Download PDF

Info

Publication number: DK169271B1
Authority: DK; Denmark
Prior art keywords: tetrahydro; dioxo; purin; cinnamic acid; compound
Prior art date: 1985-04-27

Application number

DK190486A

Other languages

Danish (da)

English (en)

Other versions

DK190486A (da

DK190486D0 (da

Inventor

Susan Mary Daluge

Harry Jefferson Leighton

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-04-27

Filing date

1986-04-24

Publication date

1994-09-26

1986-04-24 Application filed by Wellcome Found filed Critical Wellcome Found

1986-04-24 Publication of DK190486D0 publication Critical patent/DK190486D0/da

1986-10-28 Publication of DK190486A publication Critical patent/DK190486A/da

1994-09-26 Application granted granted Critical

1994-09-26 Publication of DK169271B1 publication Critical patent/DK169271B1/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/20—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK190486A 1985-04-27 1986-04-24 8-Phenylxanthinderivater, fremgansmåde til fremstilling heraf, farmaceutisk præparat indeholdende en sådan forbindelse, samt en sådan forbindelse til anvendelse til terapi DK169271B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8510758		1985-04-27
GB858510758A GB8510758D0 (en)	1985-04-27	1985-04-27	Compounds

Publications (3)

Publication Number	Publication Date
DK190486D0 DK190486D0 (da)	1986-04-24
DK190486A DK190486A (da)	1986-10-28
DK169271B1 true DK169271B1 (da)	1994-09-26

Family

ID=10578311

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK190486A DK169271B1 (da)	1985-04-27	1986-04-24	8-Phenylxanthinderivater, fremgansmåde til fremstilling heraf, farmaceutisk præparat indeholdende en sådan forbindelse, samt en sådan forbindelse til anvendelse til terapi

Country Status (22)

Country	Link
US (2)	US4879296A (de)
EP (1)	EP0203721B1 (de)
JP (1)	JPH0788381B2 (de)
KR (1)	KR860008176A (de)
AP (1)	AP22A (de)
AT (1)	ATE77088T1 (de)
AU (1)	AU581507B2 (de)
CA (1)	CA1286666C (de)
DE (1)	DE3685608T2 (de)
DK (1)	DK169271B1 (de)
ES (1)	ES8800945A1 (de)
FI (1)	FI861750A (de)
GB (1)	GB8510758D0 (de)
GR (1)	GR861107B (de)
HU (1)	HUT41027A (de)
IE (1)	IE60022B1 (de)
IL (1)	IL78605A (de)
MC (1)	MC1743A1 (de)
NO (1)	NO861643L (de)
NZ (1)	NZ215948A (de)
PT (1)	PT82451B (de)
ZA (1)	ZA863132B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4710503A (en) *	1985-02-07	1987-12-01	Euroceltique S.A.	6-thioxanthine derivatives
GB8510758D0 (en) *	1985-04-27	1985-06-05	Wellcome Found	Compounds
GB8610136D0 (en) *	1986-04-25	1986-05-29	Wellcome Found	Compounds
AT388500B (de) *	1987-10-27	1989-06-26	Wellcome Found	Antivirale 8-phenylxanthine
US5298508A (en) *	1988-07-19	1994-03-29	The United States Of America As Represented By The Department Of Health And Human Services	Irreversible inhibitors of adenosine receptors
US5310916A (en) *	1988-07-19	1994-05-10	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Trifunctional agents useful as irreversible inhibitors of A1-adenosine receptors
WO1990012797A1 (en) *	1989-04-19	1990-11-01	The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce	Sulfer-containing xanthine derivatives as adenosin antagonists
WO1991016056A1 (en) *	1990-04-16	1991-10-31	The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce	Use of purinergic receptor agonists as antineoplastic agents
DE4129603A1 (de) *	1991-09-06	1993-03-11	Thomae Gmbh Dr K	Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0541120B1 (de) *	1991-11-08	1999-05-26	Kyowa Hakko Kogyo Co., Ltd.	Xanthinderivate zur Behandlung der Demenz
EP0556778A3 (en) *	1992-02-17	1993-11-24	Kyowa Hakko Kogyo Kk	Xanthine derivatives
US5484920A (en) *	1992-04-08	1996-01-16	Kyowa Hakko Kogyo Co., Ltd.	Therapeutic agent for Parkinson's disease
US5300298A (en) *	1992-05-06	1994-04-05	The Pennsylvania Research Corporation	Methods of treating obesity with purine related compounds
TW252044B (de) *	1992-08-10	1995-07-21	Boehringer Ingelheim Kg
JP2613355B2 (ja) *	1992-09-28	1997-05-28	協和醗酵工業株式会社	パーキンソン氏病治療剤
CA2112031A1 (en) *	1992-12-24	1994-06-25	Fumio Suzuki	Xanthine derivatives
US5521315A (en) *	1993-01-12	1996-05-28	Cell Therapeutics, Inc.	Olefin substituted long chain compounds
AU6781194A (en) *	1993-05-03	1994-11-21	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
GB9312853D0 (en)	1993-06-22	1993-08-04	Euro Celtique Sa	Chemical compounds
WO1995011681A1 (en) *	1993-10-29	1995-05-04	Merck & Co., Inc.	Human adenosine receptor antagonists
US5646156A (en) *	1994-04-25	1997-07-08	Merck & Co., Inc.	Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5591776A (en)	1994-06-24	1997-01-07	Euro-Celtique, S.A.	Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en)	1994-06-24	1999-07-13	Euro-Celtique, S.A.	Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US6514949B1 (en)	1994-07-11	2003-02-04	University Of Virginia Patent Foundation	Method compositions for treating the inflammatory response
US6448235B1 (en)	1994-07-11	2002-09-10	University Of Virginia Patent Foundation	Method for treating restenosis with A2A adenosine receptor agonists
GB9415529D0 (en) *	1994-08-01	1994-09-21	Wellcome Found	Phenyl xanthine derivatives
US6025361A (en)	1994-12-13	2000-02-15	Euro-Celtique, S.A.	Trisubstituted thioxanthines
ATE247116T1 (de) *	1994-12-13	2003-08-15	Euro Celtique Sa	Arylthioxanthine
DE69531555T2 (de)	1994-12-13	2004-06-17	Euroceltique S.A.	Dreifachsubstituierte thioxanthine
US5733932A (en) *	1995-01-06	1998-03-31	The Picower Institute For Medical Research	Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions
US6268373B1 (en)	1995-06-07	2001-07-31	Euro-Celtique S.A.	Trisubstituted thioxanthines
US6166041A (en)	1995-10-11	2000-12-26	Euro-Celtique, S.A.	2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en)	1996-04-10	2000-06-13	Euro-Celtique S.A.	6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US6316423B1 (en)	1996-04-10	2001-11-13	The United States Of America As Represented By The Departmant Of Health And Human Services	Method of treating ischemic, hypoxic and anoxic brain damage
US5864037A (en)	1996-06-06	1999-01-26	Euro-Celtique, S.A.	Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US6294541B1 (en)	1996-06-06	2001-09-25	Euro-Celtique S.A.	Purine derivatives having phosphodiesterase IV inhibition activity
US5728560A (en) *	1996-06-14	1998-03-17	Enzon, Inc.	Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
US5744473A (en) *	1996-09-16	1998-04-28	Euro-Celtique, S.A.	PDE IV inhibitors: "bis-compounds"
GB9703044D0 (en)	1997-02-14	1997-04-02	Glaxo Group Ltd	Phenyl xanthine esters and amides
US6063363A (en) *	1997-05-27	2000-05-16	Goodwin; Gary J	Treatment for upper respiratory tract infections with potassium salts
BR9815170A (pt)	1997-12-12	2000-10-10	Euro Celtique S A Luxembourg	"método de obter composto aplicável no tratamento de asma em mamìferos"
US6117878A (en) *	1998-02-24	2000-09-12	University Of Virginia	8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6303619B1 (en) *	1998-03-12	2001-10-16	University Of Virginia	Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
GB9817623D0 (en)	1998-08-13	1998-10-07	Glaxo Group Ltd	Pharmaceutical compounds
US6319928B1 (en)	1998-11-30	2001-11-20	Euro-Celtique, S.A.	Purine derivatives having phosphodiesterase IV inhibition activity
US6232297B1 (en)	1999-02-01	2001-05-15	University Of Virginia Patent Foundation	Methods and compositions for treating inflammatory response
US7427606B2 (en) *	1999-02-01	2008-09-23	University Of Virginia Patent Foundation	Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) *	1999-02-01	2008-05-27	University Of Virginia Patent Foundation	Method to reduce an inflammatory response from arthritis
EP1169321A4 (de)	1999-04-02	2002-10-30	Euro Celtique Sa	Purinderivate mit phosphodiesterase-inhibitor-aktivität
US6545002B1 (en)	1999-06-01	2003-04-08	University Of Virginia Patent Foundation	Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6322771B1 (en)	1999-06-18	2001-11-27	University Of Virginia Patent Foundation	Induction of pharmacological stress with adenosine receptor agonists
US7253176B1 (en) *	2000-05-04	2007-08-07	K.U. Leuven Research & Development	Immunosuppressive effects of 8-substituted xanthine derivatives
US6670334B2 (en)	2001-01-05	2003-12-30	University Of Virginia Patent Foundation	Method and compositions for treating the inflammatory response
JP4514452B2 (ja)	2001-10-01	2010-07-28	ユニバーシティオブバージニアパテントファウンデーション	Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
MXPA04004388A (es) *	2001-11-09	2005-05-16	Cv Therapeutics Inc	Antagonistas del receptor a2b de adenosina.
US7125993B2 (en) *	2001-11-09	2006-10-24	Cv Therapeutics, Inc.	A2B adenosine receptor antagonists
US20080318983A1 (en) *	2001-11-09	2008-12-25	Rao Kalla	A2b adenosine receptor antagonists
US7317017B2 (en)	2002-11-08	2008-01-08	Cv Therapeutics, Inc.	A2B adenosine receptor antagonists
US6977300B2 (en) *	2001-11-09	2005-12-20	Cv Therapeutics, Inc.	A2B adenosine receptor antagonists
US20040072848A1 (en) *	2002-02-26	2004-04-15	Huber Brian E	Methods of treating irritable bowel syndrome and functional dyspepsia
CA2489179A1 (en) *	2002-06-12	2003-12-24	Biogen Idec Ma Inc.	Method of treating ischemia reperfusion injury using adenosine receptor antagonists
CA2516250A1 (en) *	2003-02-19	2004-09-02	Endacea, Inc.	A1 adenosine receptor antagonists
CN100590125C (zh) *	2003-05-06	2010-02-17	Cv医药有限公司	作为a2b腺苷受体拮抗剂的黄嘌呤衍生物
US7247639B2 (en) *	2003-06-06	2007-07-24	Endacea, Inc.	A1 adenosine receptor antagonists
WO2006028618A1 (en) *	2004-08-02	2006-03-16	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) *	2004-08-02	2006-03-02	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs having a2a agonist activity
AU2005267706B2 (en) *	2004-08-02	2011-12-08	University Of Virginia Patent Foundation	2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
AU2005282860B2 (en) *	2004-09-01	2012-03-22	Gilead Sciences, Inc.	Method of wound healing using A2B adenosine receptor antagonists
WO2007092936A2 (en) *	2006-02-08	2007-08-16	University Of Virginia Patent Foundation	Method to treat gastric lesions
US8178509B2 (en)	2006-02-10	2012-05-15	University Of Virginia Patent Foundation	Method to treat sickle cell disease
US8188063B2 (en)	2006-06-19	2012-05-29	University Of Virginia Patent Foundation	Use of adenosine A2A modulators to treat spinal cord injury
US8193200B2 (en)	2007-01-04	2012-06-05	University Of Virginia Patent Foundation	Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
US8058259B2 (en) *	2007-12-20	2011-11-15	University Of Virginia Patent Foundation	Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2602795A (en)	1950-06-24	1952-07-08	Searle & Co	Hydroxyalkyl alkyl derivatives of 5-nitroso-6-amino-1, 2, 3, 4-tetrahydro-2, 4-pyrimidinedione
US4452788A (en) *	1982-04-21	1984-06-05	Warner-Lambert Company	Substituted 8-phenylxanthines
US4593095A (en) *	1983-02-18	1986-06-03	The Johns Hopkins University	Xanthine derivatives
US4612315A (en) *	1984-10-26	1986-09-16	The United States Of America As Represented By The Department Of Health And Human Services	Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives
US4696932A (en) *	1984-10-26	1987-09-29	The United States Of America As Represented By The Department Of Health And Human Services	Biologically-active xanthine derivatives
GB8510758D0 (en) *	1985-04-27	1985-06-05	Wellcome Found	Compounds
DE3522230A1 (de) *	1985-06-21	1987-01-02	Thomae Gmbh Dr K	Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

1985
- 1985-04-27 GB GB858510758A patent/GB8510758D0/en active Pending
1986
- 1986-04-23 IL IL78605A patent/IL78605A/xx unknown
- 1986-04-24 NZ NZ215948A patent/NZ215948A/xx unknown
- 1986-04-24 PT PT82451A patent/PT82451B/pt unknown
- 1986-04-24 AU AU56707/86A patent/AU581507B2/en not_active Expired
- 1986-04-24 DK DK190486A patent/DK169271B1/da not_active IP Right Cessation
- 1986-04-25 EP EP86303171A patent/EP0203721B1/de not_active Expired - Lifetime
- 1986-04-25 AT AT86303171T patent/ATE77088T1/de not_active IP Right Cessation
- 1986-04-25 KR KR1019860003211A patent/KR860008176A/ko not_active Application Discontinuation
- 1986-04-25 ES ES554380A patent/ES8800945A1/es not_active Expired
- 1986-04-25 AP APAP/P/1986/000036A patent/AP22A/en active
- 1986-04-25 FI FI861750A patent/FI861750A/fi not_active Application Discontinuation
- 1986-04-25 CA CA000507576A patent/CA1286666C/en not_active Expired - Fee Related
- 1986-04-25 HU HU861730A patent/HUT41027A/hu unknown
- 1986-04-25 JP JP61094957A patent/JPH0788381B2/ja not_active Expired - Lifetime
- 1986-04-25 GR GR861107A patent/GR861107B/el unknown
- 1986-04-25 MC MC861834A patent/MC1743A1/xx unknown
- 1986-04-25 ZA ZA863132A patent/ZA863132B/xx unknown
- 1986-04-25 DE DE8686303171T patent/DE3685608T2/de not_active Expired - Lifetime
- 1986-04-25 NO NO861643A patent/NO861643L/no unknown
- 1986-04-25 US US06/856,719 patent/US4879296A/en not_active Expired - Lifetime
- 1986-04-28 IE IE110486A patent/IE60022B1/en not_active IP Right Cessation
1989
- 1989-08-29 US US07/400,464 patent/US4981857A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA1286666C (en)	1991-07-23
MC1743A1 (fr)	1987-02-26
US4879296A (en)	1989-11-07
GR861107B (en)	1986-08-04
IL78605A (en)	1989-07-31
DE3685608D1 (de)	1992-07-16
IE861104L (en)	1986-10-27
NZ215948A (en)	1989-10-27
IL78605A0 (en)	1986-08-31
DE3685608T2 (de)	1992-12-24
DK190486A (da)	1986-10-28
ATE77088T1 (de)	1992-06-15
JPS6242986A (ja)	1987-02-24
AU5670786A (en)	1986-10-30
FI861750A (fi)	1986-10-28
HUT41027A (en)	1987-03-30
PT82451A (en)	1986-05-01
NO861643L (no)	1986-10-28
GB8510758D0 (en)	1985-06-05
ES8800945A1 (es)	1987-12-01
KR860008176A (ko)	1986-11-12
ES554380A0 (es)	1987-12-01
DK190486D0 (da)	1986-04-24
JPH0788381B2 (ja)	1995-09-27
AU581507B2 (en)	1989-02-23
PT82451B (pt)	1988-11-30
EP0203721B1 (de)	1992-06-10
US4981857A (en)	1991-01-01
EP0203721A3 (en)	1988-06-08
IE60022B1 (en)	1994-05-18
AP22A (en)	1988-07-20
AP8600036A0 (en)	1986-02-01
ZA863132B (en)	1987-12-30
FI861750A0 (fi)	1986-04-25
EP0203721A2 (de)	1986-12-03

Publication	Publication Date	Title
DK169271B1 (da)	1994-09-26	8-Phenylxanthinderivater, fremgansmåde til fremstilling heraf, farmaceutisk præparat indeholdende en sådan forbindelse, samt en sådan forbindelse til anvendelse til terapi
KR970001528B1 (ko)	1997-02-11	신규 키산틴 유도체
DE60204452T2 (de)	2005-12-15	Pyrazolo[1,5a]Pyridinderivate
EP0607607B1 (de)	1996-09-18	Xanthin Derivate
US6545000B1 (en)	2003-04-08	[1,2,4]triazolo[1,5-c]pyrimidine derivatives
KR20010085314A (ko)	2001-09-07	6원 헤테로시클릭 고리와 축합된 치환된 피라졸 유도체
EP1939197A1 (de)	2008-07-02	8-Ethinylxanthinderivate als selektive Antagonisten des A2A-Rezeptors
WO1990008144A1 (en)	1990-07-26	Bis-aza-bicyclic anxiolytic agents
JP3116230B2 (ja)	2000-12-11	三環式縮合ピリミジン誘導体
PT98366B (pt)	1999-01-29	Processo para a preparacao de novos derivados de tiazolilo substituido e de pitidinilo substituido e de composicoes farmaceuticas que os contem
EP0177087B1 (de)	1991-01-30	1H-Indol-3-yl enthaltende 1,3-Dimethyl-1-H-purine-2,6-dione
AU680241B2 (en)	1997-07-24	Xanthine derivatives as adenosine A1 receptor antagonists
EP0865442B1 (de)	2000-07-05	Imidazo(1,2-a)quinoxalin-4-amine als adenosin-antagonisten, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
SK114498A3 (en)	1999-02-11	Imidazo triazolo pyrimidinone derivatives, method of preparing them and their use
US5015647A (en)	1991-05-14	Method for treating viral infections
US5017577A (en)	1991-05-21	Methods for treating viral infection
IE780310L (en)	1978-08-14	Heterocyclopyrimidines
PL158865B1 (pl)	1992-10-30	lo/-3H,6H-1,4,5a,8a-tetraazaacenaftylen-3-onów PL PL PL PL PL PL PL PL
WO2022107044A1 (en)	2022-05-27	Prevention and/or treatment of cns disorders

Legal Events

Date	Code	Title	Description
1994-09-26	B1	Patent granted (law 1993)
2006-05-15	PUP	Patent expired